Search Results
7 items found for "Prostatitis"
- Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin ...
September 2022 Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans "Men with advanced prostate cancer are treated by androgen deprivation therapy but the disease recurs as incurable castration-resistant prostate cancer (CRPC), requiring new Interrogation of prostate cancer patient sample data revealed that coexpression of AVPR1A and AVPR2 is
- Odorant receptors – a bit of smell for drug discovery
whereas OR51E1 and OR51E2 represent ubiquitously expressed ORs, although there are highly increased in prostate tissue, especially in prostate cancer (Maßberg D. and Hatt H. 2018). OR51E1 and OR51E2, initially assumed to be GPCRs only expressed in prostate tissue, play a role in prostate cancer epithelial cells proliferation via activation by β-ionone which initiates prostate cancer cell
- 📰 GPCR Weekly News, March 18 to 24, 2024
more Elucidation of active components and target mechanism in Jinqiancao granules for the treatment of prostatitis and benign prostatic hyperplasia GPCRs in Cardiology, Endocrinology, and Taste Blockade of endothelial
- 📰 GPCR Weekly News, May 22 to 28, 2023
The intertwining roles of caveolin, oxytocin receptor, and the associated signalling pathways in prostate
- 📰 GPCR Weekly News, June 5 to 11, 2023
Autocrine Proteinase-Activated Receptor (PAR) signaling in PC3 prostate cancer cells.
- 📰 GPCR Weekly News, June 26 to July 2, 2023
Autocrine proteinase-activated receptor signaling in PC3 prostate cancer cells.
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands ...
To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs In a proof-of-principle study, we succeeded in showing that our CCR9-PROTAC is able to reduce CCR9 levels